WHO ICTRP trial
Lapatinib and Whole Brain Radiotherapy for patients with brain metastases from…
EUCTR2009-013128-22-GR · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2009-013128-22-GR |
|---|---|
| Public title | Lapatinib and Whole Brain Radiotherapy for patients with brain metastases from lung and breast tumors. A phase II study of the Hellenic Cooperative Oncology Group (HeCOG). |
| Scientific title | Lapatinib and Whole Brain Radiotherapy for patients with brain metastases from lung and breast tumors. A phase II study of the Hellenic Cooperative Oncology Group (HeCOG). |
| Primary sponsor | Hellenic Cooperative Oncology Group |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Greece |
| Conditions | Patients with brain metastases from lung and breast tumors MedDRA version: 12.0 Level: LLT Classification code 10006128 Term: Brain metastases |
| Interventions | Trade Name: Tyverb Product Name: Tyverb Pharmaceutical Form: Coated tablet INN or Proposed INN: Lapatinib CAS Number: 388082-78-8 Current Sponsor code: GW572016 Other descriptive name: Lapatinib ditosylate monohydrate Concentration unit: mg… |
| Registration date | Jul 10, 2009 |
| Secondary IDs | HE 42/09 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: